Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of intranasal BPL-003 in treatment-resistant depression
2022-003743-10Phase 2Active
- Sponsor
- Beckley Psytech
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of mebufotenin in treatment-resistant depression (TRD) and major depressive disorder (MDD) (4 arms), sponsored by Beckley Psytech. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Jan 2023; status: active.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2022-003743-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003743-10.